BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 19759151)

  • 21. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
    Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Junctional and somatic hypermutation-induced CX
    Yi C; Xia J; He L; Ling Z; Wang X; Yan Y; Wang J; Zhao X; Fan W; Sun X; Zhang R; Ye S; Zhang R; Xu Y; Ma L; Zhang Y; Zhou H; Huang Z; Niu J; Long G; Lu J; Zhong J; Sun B
    Cell Mol Immunol; 2021 Mar; 18(3):675-685. PubMed ID: 32235917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
    Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
    J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81.
    Allander T; Drakenberg K; Beyene A; Rosa D; Abrignani S; Houghton M; Widell A; Grillner L; Persson MAA
    J Gen Virol; 2000 Oct; 81(Pt 10):2451-2459. PubMed ID: 10993933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
    Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
    PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference.
    Sautto G; Mancini N; Diotti RA; Solforosi L; Clementi M; Burioni R
    Antiviral Res; 2012 Oct; 96(1):82-9. PubMed ID: 22898087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
    Rosa D; Campagnoli S; Moretto C; Guenzi E; Cousens L; Chin M; Dong C; Weiner AJ; Lau JY; Choo QL; Chien D; Pileri P; Houghton M; Abrignani S
    Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1759-63. PubMed ID: 8700831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies.
    Pantua H; Diao J; Ultsch M; Hazen M; Mathieu M; McCutcheon K; Takeda K; Date S; Cheung TK; Phung Q; Hass P; Arnott D; Hongo JA; Matthews DJ; Brown A; Patel AH; Kelley RF; Eigenbrot C; Kapadia SB
    J Mol Biol; 2013 Jun; 425(11):1899-1914. PubMed ID: 23458406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.
    Sabo MC; Luca VC; Prentoe J; Hopcraft SE; Blight KJ; Yi M; Lemon SM; Ball JK; Bukh J; Evans MJ; Fremont DH; Diamond MS
    J Virol; 2011 Jul; 85(14):7005-19. PubMed ID: 21543495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.
    Owsianka AM; Tarr AW; Keck ZY; Li TK; Witteveldt J; Adair R; Foung SKH; Ball JK; Patel AH
    J Gen Virol; 2008 Mar; 89(Pt 3):653-659. PubMed ID: 18272755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.
    Keck ZY; Li TK; Xia J; Gal-Tanamy M; Olson O; Li SH; Patel AH; Ball JK; Lemon SM; Foung SK
    J Virol; 2008 Jun; 82(12):6061-6. PubMed ID: 18400849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
    McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
    J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope.
    Petit MA; Jolivet-Reynaud C; Peronnet E; Michal Y; Trépo C
    J Biol Chem; 2003 Nov; 278(45):44385-92. PubMed ID: 12882983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    Ahsan A; Dar S; Hassan F; Ghafoor F; Yousuf MH; Shahzad-Ul-Hussan S
    PLoS One; 2021; 16(8):e0256816. PubMed ID: 34449828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.
    Mesalam AA; Desombere I; Farhoudi A; Van Houtte F; Verhoye L; Ball J; Dubuisson J; Foung SKH; Patel AH; Persson MAA; Leroux-Roels G; Meuleman P
    Virology; 2018 Jan; 514():30-41. PubMed ID: 29128754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity.
    Keck ZY; Sung VM; Perkins S; Rowe J; Paul S; Liang TJ; Lai MM; Foung SK
    J Virol; 2004 Jul; 78(13):7257-63. PubMed ID: 15194801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
    Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
    Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.